Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Milwaukee, Wisconsin

Phase 3 cancer trials in Milwaukee, WI

49 Phase 3 cancer studies are recruiting participants at sites in Milwaukee as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Milwaukee at a glance

Breast cancer studies recruiting in Milwaukee

Basic details from each study's public record (the 30 most recently updated of 49). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT06058377 · updated
  2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT05879926 · updated
  3. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT06748222 · updated
  4. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07173751 · updated
  5. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07492641 · updated
  6. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Aurora St Luke's Medical Center
    Registry record
    NCT07062965 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Lung cancer studies recruiting in Milwaukee

  1. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07388524 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Ascension Columbia Saint Mary's Hospital-Milwaukee Campus · Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT06096844 · updated
  4. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Aurora St. Luke's Medical Center
    Registry record
    NCT06758401 · updated
  5. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Ascension Columbia St. Mary's
    Registry record
    NCT06793215 · updated
  6. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT04181060 · updated
  7. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06890598 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Milwaukee

  1. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Medical College of Wisconsin ( Site 0020)
    Registry record
    NCT06136624 · updated
  2. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Ascension Columbia Saint Mary's Hospital-Milwaukee Campus · Medical College of Wisconsin · Zablocki Veterans Administration Medical Center
    Registry record
    NCT06931340 · updated
  3. Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07200830 · updated
  4. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Medical College of Wisconsin ( Site 0008)
    Registry record
    NCT06925737 · updated
  5. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT05946213 · updated
  6. A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Medical College of Wisconsin ( Site 0020)
    Registry record
    NCT06136650 · updated
  7. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

    • Phase 3
    • Ages 18 to 100
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06855277 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Melanoma studies recruiting in Milwaukee

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Lymphoma studies recruiting in Milwaukee

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06337318 · updated
  2. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Medical College of Wisconsin
    Registry record
    NCT06724237 · updated
  3. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
    Registry record
    NCT05675410 · updated
  4. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07188558 · updated
  5. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Medical College of Wisconsin
    Registry record
    NCT03150693 · updated
  6. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Medical College of Wisconsin
    Registry record
    NCT05976763 · updated
  7. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Medical College of Wisconsin
    Registry record
    NCT07215910 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Milwaukee

  1. Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Froedtert Hospital and the Medical College of Wisconsin
    Registry record
    NCT06943755 · updated
  2. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Froedtert Hospital and the Medical College of Wisconsin
    Registry record
    NCT07252232 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.

Ask about studies near Milwaukee

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Wisconsin

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call